Dr. Dennis Gross Alpha Beta on the Spot Eliminator

Description

Dr. Dennis Gross Alpha Beta® On The Spot Eliminator is an acne treatment gel formulated with 2% salicylic acid. This product is designed to target and reduce the appearance of acne. It is presented in a dosage form of a gel, with a total volume of 1.0 fluid ounce (30 ml ℮).

Uses and Indications

This drug is indicated for the treatment of acne. It penetrates the pores to eliminate most acne blemishes and blackheads, while also helping to prevent the development of new acne blemishes and blackheads.

Dosage and Administration

Healthcare professionals should ensure that the skin is thoroughly cleaned prior to the application of this product. The recommended application involves covering the entire affected area with a thin layer. This can be done one to three times daily, depending on the patient's needs and the physician's guidance.

To minimize the risk of excessive drying of the skin, it is advisable to initiate treatment with one application per day. Based on the patient's response and tolerance, the frequency may be gradually increased to two or three times daily as necessary or as directed by a healthcare provider.

In cases where the patient experiences bothersome dryness or peeling, it is recommended to reduce the frequency of application to once daily or every other day to alleviate these symptoms.

Contraindications

There are no specific contraindications listed for this product. However, it is essential to adhere to the following precautions:

Keep out of reach of children. In the event of accidental ingestion, seek medical assistance or contact a Poison Control Center immediately. Additionally, avoid contact with eyes to prevent irritation or injury.

Warnings and Precautions

For external use only. It is imperative to avoid contact with the eyes to prevent irritation or injury.

The concurrent use of this product with other topical acne medications may increase the likelihood of skin irritation and dryness. In the event that irritation occurs, it is recommended to limit the use to one topical acne medication at a time to mitigate adverse effects.

This product should be kept out of reach of children. In the case of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is advised.

Side Effects

Patients should be aware that this product is intended for external use only. It is important to avoid contact with the eyes during application to prevent potential irritation.

In clinical use, skin irritation and dryness have been reported as common adverse reactions. The likelihood of these reactions may increase if the product is used concurrently with other topical acne medications. Therefore, if patients experience irritation, it is recommended to limit the use to one topical acne medication at a time to mitigate these effects.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications should be considered to alleviate symptoms. Monitoring for signs of skin irritation is recommended when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Dr. Dennis Gross Alpha Beta on the Spot Eliminator (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of Dr. Dennis Gross Alpha Beta On The Spot Eliminator in geriatric patients. The prescribing information does not provide guidance on dosage adjustments, safety concerns, or special precautions for elderly patients. Therefore, healthcare providers should exercise caution and consider individual patient factors when prescribing this medication to geriatric patients, as the absence of specific data necessitates careful monitoring and assessment of treatment outcomes in this population.

Pregnancy

Pregnant patients should be aware that the safety of this medication during pregnancy has not been specifically established. There are no available data regarding the potential risks or fetal impacts associated with the use of this medication in pregnant individuals. Healthcare professionals are advised to consider the lack of information when prescribing this medication to women of childbearing potential and to weigh the potential benefits against any unknown risks. It is recommended that pregnant patients discuss their treatment options with their healthcare provider to ensure informed decision-making regarding their health and the health of the fetus.

Lactation

There are no specific warnings or recommendations regarding the use of this product by lactating mothers. Additionally, there is no information available concerning the potential for excretion in breast milk or any effects on breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the prescribing information regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of specific guidance necessitates careful evaluation of the patient's overall health status and liver function.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should be contacted without delay, or the individual should reach out to a Poison Control Center for guidance.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. It is recommended that healthcare providers assess the situation thoroughly, including the amount ingested and the time of ingestion, to determine the appropriate course of action.

Monitoring for symptoms related to overdosage is critical, although specific symptoms are not detailed in the provided information. Healthcare professionals should remain vigilant and prepared to manage any complications that may arise as a result of the overdosage.

In summary, swift action and professional medical evaluation are imperative in cases of suspected overdosage to ensure patient safety and effective management.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children. Instruct patients that if the medication is swallowed, they should seek medical help or contact a Poison Control Center immediately.

Patients should be cautioned to avoid contact with their eyes while using this medication. It is important to inform them that if the medication does come into contact with the eyes, they should rinse thoroughly with water and seek medical attention if irritation persists.

Additionally, healthcare providers should discuss the potential for skin irritation and dryness, particularly if patients are using another topical acne medication concurrently. It is recommended that patients use only one topical acne medication at a time to minimize the risk of irritation. If patients experience any signs of irritation, they should be advised to discontinue use and consult their healthcare provider for further guidance.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). It is essential to protect the product from light to prevent degradation. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The product is administered topically. Clinicians should inform patients that the formulation contains alpha hydroxy acid(s) (AHAs), which may heighten skin sensitivity to sunlight and increase the risk of sunburn. It is advisable for patients to use sunscreen daily, regardless of whether they are using this product, to mitigate the risks associated with sun exposure.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Dr. Dennis Gross Alpha Beta on the Spot Eliminator, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)